Overview

A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 in Participants With Relapsed or Refractory T-cell Lymphomas in Japan

Status:
Recruiting
Trial end date:
2030-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 in participants with relapsed or refractory T-cell lymphomas in Japan.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Bristol-Myers Squibb